Candidemia in cancer and bone marrow transplant patients: A 10-year retrospective analysis

Infections in Medicine

Volumn 21, Issue 1, 2004, Pages 37-42

  Strickland Marmol, Leah B ^a,b   Vincent, Albert L ^b   Laartz, Brent W ^d   Sandin, Ramon ^b,c   Greene, John N ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d Univ of South Florida Coll of Med ^*

Author keywords

Bone marrow transplant; Candidemia; Fluconazole

Indexed keywords

ANTIVIRUS AGENT; CEFTAZIDIME; FLUCONAZOLE; GENTAMICIN; VANCOMYCIN;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD CULTURE; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER PATIENT; CANDIDA ALBICANS; CANDIDIASIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FUNGUS CULTURE; FUNGUS ISOLATION; HEMATOLOGIC MALIGNANCY; HUMAN; INFANT; INFECTION PREVENTION; MALE; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; RETROSPECTIVE STUDY; REVIEW; SPECIES DIFFERENCE;

EID: 0842324073     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol. 2002;40:3489-3492.
2. Clift RA. Candidiasis in the transplant patient. Am J Med. 1984;77(suppl 4D):34-38.
3. Tollemar J, Ringden O, Bostrom L, et al. Variables predicting deep fungal infections in bone marrow transplant patients. Bone Marrow Transplant. 1989;4:635-641.
4. Baran J Jr, Muckatira B, Khatib R. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand J Infect Dis. 2001;33:137-139.
5. Abi-Said D, Anaissie E, Uzun O, et al. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis, 1997;24:1122-1128.
6. Marr K, Seidel K, White T, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309-316.
7. Alangaden G, Chandrasekar PH, Bailey E, Khaliq Y. Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. Bone Marrow Transplant. 1994;14: 919-924.
8. Nucci M, Silveira MI, Spector N, et al. Fungemia in cancer patients in Brazil: predominance of non-albicans species. Mycopathologia. 1998; 141:65-68.
9. Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med. 2002;112:380-385.
10. Hope W, Morton A, Eisen DP. Increase in prevlence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect. 2002;50: 56-65.
11. Diekema DJ, Messer SA, Brueggemann AB, et al. Epidemiology of candidemia: 3-year results from the emerging infections and epidemiology of Iowa organisms study. J Clin Microbiol. 2002;40:1298-1302
12. Abbas J, Bodey GP, Hanna HA, et al. Candida krusei fungemia. An escalating serious infection in immunocompromised patients. Arch Intern Med. 2000;160:2659-2664.
13. Safdar A, van Rhee F, Henslee-Downey JP, et al. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marTow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 2001;28:873-878.
14. Martin MV. The use of fluconazole and intrconazole in the treatment of Candida albicans infections: a review. J Antimicrob Chemother. 1999; 44:429-437.
15. Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis. 2002;21:209-211.
16. Verfaillie C, Weisdorf D, Haake R, et al. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant. 1991;8:177-184.
17. Collin B, Clancy CJ, Nguyen MH. Antifungal resistance in non-albicans Candida species. Drug Resist Updat. 1999;2:9-14.
18. Pfaller MA, Jones RN, Doern GV, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother. 2000;44:747-751.
19. Rogers TR. Antifungal drug resistance: does it matter? Int J Infect Dis. 2002;6(suppl 1):S47-S53.